Literature DB >> 3121350

Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus.

K W Jauch1, W Hartl, B Guenther, M Wicklmayr, K Rett, G Dietze.   

Abstract

Bradykinin infusion has been shown to improve glucose metabolism in non-insulin-dependent diabetic subjects (NIDD). Therefore, we tested the following hypothesis: inhibition of Kininase II, the bradykinin (BK) degrading enzyme, by captopril may also improve glucose metabolism in NIDD. Immediate effects of captopril on total body and peripheral glucose disposal were examined in five normotensive, normal weight NIDD and compared with five NIDD control subjects, well matched for age, weight and degree of fasting hyperglycaemia. The euglycaemic insulin clamp technique was employed in combination with the forearm catheter technique. After 90 min of insulin infusion a single dose of 25 mg captopril was administered orally, whereas in the control group a placebo was given. Captopril lead to a significant rise in total body glucose disposal and forearm glucose uptake, while in the control group no change was observed. Simultaneously, captopril lead to reduction in muscular release of lactate and pyruvate. We conclude that these results demonstrate the stimulatory effect of captopril on insulin-induced glucose disposal of the whole body, which appears to be a result of increased glucose utilization by peripheral tissues. Because of the described insulin-like activity of bradykinin, the concomitant accumulation of local kinins by captopril-induced inhibition of kininase II may represent an attractive hypothesis to explain the generated data sufficiently.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121350     DOI: 10.1111/j.1365-2362.1987.tb01141.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  25 in total

Review 1.  [Intensive insulin therapy in sepsis. Improvement of survival chances?].

Authors:  M G Jeschke
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

Review 2.  Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).

Authors:  S O'Byrne; J Feely
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 3.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 4.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 5.  Antihypertensive agents, insulin sensitivity, and new-onset diabetes.

Authors:  Pantelis A Sarafidis; Samy I McFarlane; George L Bakris
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

Review 6.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

7.  Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension.

Authors:  T Pollare; H Lithell; I Selinus; C Berne
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

Review 8.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

9.  Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension.

Authors:  T Baba; T Kodama; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications.

Authors:  Elena Bernobich; Luisa de Angelis; Carlos Lerin; Giuseppe Bellini
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.